Cargando…

Pharmacokinetics, Safety, and Efficacy of Gadopiclenol in Pediatric Patients Aged 2 to 17 Years

OBJECTIVES: The aim of this study was to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of gadopiclenol, a new high-relaxivity gadolinium-based contrast agent, in children aged 2 to 17 years. MATERIALS AND METHODS: Children scheduled to undergo contrast-enhanced magnetic resonance i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jurkiewicz, Elżbieta, Tsvetkova, Silvia, Grinberg, Anna, Pasquiers, Blaise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390233/ https://www.ncbi.nlm.nih.gov/pubmed/35318970 http://dx.doi.org/10.1097/RLI.0000000000000865

Ejemplares similares

Review of the Efficacy and Safety of Gadopiclenol: A Newly Emerging Gadolinium-Based Contrast Agent
por: Alsogati, Emad, et al.
Publicado: (2023)

Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial
por: Loevner, Laurie A., et al.
Publicado: (2023)

A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years
por: Scala, Mario, et al.
Publicado: (2018)

Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity
por: Robic, Caroline, et al.
Publicado: (2019)

Pharmacokinetics and safety of a single dose of telavancin in pediatric subjects 2–17 years of age
por: Bradley, John S., et al.
Publicado: (2023)

Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine
por: Violas, Xavier, et al.
Publicado: (2022)

Review of the Existing Translational Pharmacokinetics Modeling Approaches Specific to Monoclonal Antibodies (mAbs) to Support the First-In-Human (FIH) Dose Selection
por: Pasquiers, Blaise, et al.
Publicado: (2022)

Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab
por: Pasquiers, Blaise, et al.
Publicado: (2023)

Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy
por: Renfroe, J. Ben, et al.
Publicado: (2019)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
por: Mintz, Mark, et al.
Publicado: (2019)

Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
por: Roilides, Emmanuel, et al.
Publicado: (2020)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Guaifenesin Pharmacokinetics Following Single‐Dose Oral Administration in Children Aged 2 to 17 Years
por: Thompson, Gary A., et al.
Publicado: (2016)

Safety, pharmacokinetics and efficacy of artemisinins in pregnancy
por: Ades, Veronica
Publicado: (2011)

Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients
por: Muse, Derek, et al.
Publicado: (2019)

Case Report: Adenosine kinase deficiency diagnosed 10 years after liver transplantation: Novel phenotypic insights
por: Lipiński, Patryk, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
por: Gooderham, M, et al.
Publicado: (2014)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

Palmitoylethanolamide for the treatment of pain: pharmacokinetics, safety and efficacy
por: Gabrielsson, Linda, et al.
Publicado: (2016)

Safety of the Use of Face Masks in Pediatric Age
por: Lubrano, Riccardo, et al.
Publicado: (2022)

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1
por: Giaquinto, Carlo, et al.
Publicado: (2018)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
por: Kingsbury, Daniel J., et al.
Publicado: (2014)

S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
por: Heeney1, Matthew, et al.
Publicado: (2023)

Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria
por: Rodríguez, Mónica, et al.
Publicado: (2020)

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to < 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study
por: Schulte, Johannes H, et al.
Publicado: (2023)

Safety and Efficacy of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in the Treatment of Extensive Scalp Psoriasis in Adolescents Ages 12 to 17 Years
por: Eichenfield, Lawrence F, et al.
Publicado: (2015)

Long-term safety and tolerability of valsartan in children aged 6 to 17 years with hypertension
por: Lou-Meda, Randall, et al.
Publicado: (2018)

Safety and Efficacy of Maxitrol in Pediatric Age Group Below Two Years With Adenoid Hypertrophy: A Retrospective Cohort Study
por: Halawani, Mohammed, et al.
Publicado: (2021)

Traditional and New Methods of Bone Age Assessment-An Overview
por: Prokop-Piotrkowska, Monika, et al.
Publicado: (2021)

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
por: Rosa, Bruno Rodrigues, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs
por: Gamble, Lauri-Jo, et al.
Publicado: (2018)

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B
por: Groll, Andreas H, et al.
Publicado: (2019)

Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge
por: Di Salvo, Alessandra, et al.
Publicado: (2023)

Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age
por: Belshe, Robert B., et al.
Publicado: (2010)

Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics—CheckMate 908
por: Dunkel, Ira J, et al.
Publicado: (2023)

The efficacy and safety of mivacurium in pediatric patients
por: Zeng, Ruifeng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_840qluu1o64768hkr44mniaj6s